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Abstract
Background: Molecular characterization of collagen-VI related myopathies currently relies on standard sequencing,
which yields a detection rate approximating 75-79% in Ullrich congenital muscular dystrophy (UCMD) and 60-65%
in Bethlem myopathy (BM) patients as PCR-based techniques tend to miss gross genomic rearrangements as well
as copy number variations (CNVs) in both the coding sequence and intronic regions.
Methods: We have designed a custom oligonucleotide CGH array in order to investigate the presence of CNVs in
the coding and non-coding regions of COL6A1, A2, A3, A5 and A6 genes and a group of genes functionally related
to collagen VI. A cohort of 12 patients with UCMD/BM negative at sequencing analysis and 2 subjects carrying a
single COL6 mutation whose clinical phenotype was not explicable by inheritance were selected and the
occurrence of allelic and genetic heterogeneity explored.
Results: A deletion within intron 1A of the COL6A2 gene, occurring in compound heterozygosity with a small
deletion in exon 28, previously detected by routine sequencing, was identified in a BM patient. RNA studies
showed monoallelic transcription of the COL6A2 gene, thus elucidating the functional effect of the intronic
deletion. No pathogenic mutations were identified in the remaining analyzed patients, either within COL6A genes,
or in genes functionally related to collagen VI.
Conclusions: Our custom CGH array may represent a useful complementary diagnostic tool, especially in recessive
forms of the disease, when only one mutant allele is detected by standard sequencing. The intronic deletion we
identified represents the first example of a pure intronic mutation in COL6A genes.
Background
M u t a t i o n si nt h eg e n e se n c o d i n gc o l l a g e nV I( COL6A1,
COL6A2 and COL6A3) result in two major phenotypes:
Bethlem myopathy [BM, OMIM #158810] and Ullrich
congenital muscular dystrophy [UCMD, OMIM
#254090]. Despite BM being classically reported as an
autosomal dominant condition due to heterozygous
COL6 mutations [1,2], we and others have recently
described autosomal recessive BM patients [3,4]. In con-
trast, the allelic form UCMD was initially considered to
be an autosomal recessive disorder, with homozygous or
compound heterozygous mutations occurring in all
three COL6 genes [2], although a few double heterozy-
gous mutations in two different COL6 genes have also
been described [5]. Recently, however, up to 50% of
UCMD cases have been found to carry only one
mutated allele, indicating autosomal dominant inheri-
tance [5-7]. Thus far, roughly 100 different mutations in
COL6 genes have been associated with either UCMD or
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The distribution ofm u t a t i o n sa l o n gCOL6 genes is
rather uniform and lacks mutation hot spots, therefore
these patients require extensive genotyping, which is cur-
rently performed by genomic or cDNA sequencing [1,5].
Nevertheless, a relevant proportion of patients clinically
diagnosed as having a collagen-VI related myopathy still
lack molecular characterization. In fact, with currently
available diagnostic tools, the detection rate of mutations
of COL6 genes varies from 60-65% in BM cases and 75-
79% in UCMD patients [5]. The majority of these muta-
tions are small variations like missense, frame-shifting,
ins-del or point mutations which lead to a splicing defect.
Large, multi-exon deletions of the COL6A1 gene, invol-
ving both exonic and intronic regions and thus detectable
by mRNA analysis, have been reported as causative
mutations in three patients [9,10]. One limitation of
PCR-based genome analysis techniques is their inability
to detect gross CNVs, as well as atypical mutations,
which could account for a significant proportion of unde-
tected COL6 mutations. On the other hand, the relatively
low rate of mutation detection in COL6 genes could be
due to the genetic heterogeneity of these diseases. Thus,
mutations in genes functionally related to collagen VI
could theoretically underlie UCMD and BM phenocopies
and/or be responsible for secondary collagen VI defects
[11]. In order to test this hypothesis, we selected 12
UCMD/BM patients who were found to be negative
upon extensive sequence analysis of the three COL6
genes, and two patients carrying only one mutation,
deemed insufficient to explain the clinical phenotype, it
being inherited from a healthy parent.
The occurrence of both allelic and genetic heterogene-
ity was explored in these patients by using an innovative
oligonucleotide array-based comparative genomic hybri-
dization (CGH) approach able to detect CNVs in COL6
genes, as well as in other genes functionally related to
collagen VI.
A deep intronic deletion in the COL6A2 gene was dis-
covered in one BM patient, with a single mutation
i n h e r i t e df r o mt h eh e a l t h ym o t h e ri d e n t i f i e da ts e q u e n -
cing analysis. Subsequently, the functional effect of the
identified mutation was demonstrated via RNA studies.
In the remaining patients, only non pathogenic CNVs
were identified.
Methods
Genome sequence analysis
Patients’ genomic DNA was extracted from peripheral
blood lymphocytes after informed consent and approval
by the local ethics committee was obtained (approval
number 7/2009). PCR primers (sequences are available
upon request) were designed to amplify all the 107 exons
of the COL6 genes, as well as their flanking intronic
regions. Amplified fragments were directly sequenced
using a BigDye Terminator v3.1 Cycle sequencing system
on the automated ABI 3130 Genetic Analyzer (Applied
Biosystems, Foster City, CA).
In order to try to attempt amplification across the
deletion within COL6A2 intron 1A, identified by the
CGH-array, the following oligonucleotides were posi-
tioned outside the maximum theoretical deleted region:
F1 CCCTGAATTCCTGGACATGAT; R1 GAACGTC-
CATCCTCCCTGAT; and flanking the region identified
by the two deleted probes (F2 AGATCCACAGCCAC-
GACTT; R2 GGCCTCACTGTGCTGCTG) (Figure 1).
Long-range PCR was performed using LA-Taq polymer-
ase and 40 cycles at 64°C.
Micro-array design, hybridization and data analysis
COL6-CGH array design was performed using the high-
density aCGH search function of the web-based Agilent
eArray database, version 4.5 [12].
The genomic regions corresponding to COL6A1-A2-
A3-A5 and -A6 genes as well as a group of genes func-
t i o n a l l yr e l a t e dt oc o l l a g e nV I( T a b l e1 )[ 1 3 - 2 1 ]w e r e
masked for repetitive elements and converted into a
10.197 probe set by selecting the maximum number of
exonic and intronic 60 mer oligonucleotide probes avail-
able in the Agilent database. This probe set was enriched
with 377 probes in triplicate, covering the regions of
COL6A1, 2 and 3 genes not investigated by the Agilent
CGH probe database. The final mean resolution for these
genes was one probe every 320 bp. In order to reach the
15K array format, each array was filled with control
probes from all the chromosomes (2851).
The array format utilized was 8 × 15K, made up of
eight identical 15K arrays on a single slide, thereby per-
mitting simultaneous analysis of eight different samples.
Genomic DNA was extracted from the patients’ whole
blood or cultured fibroblasts by a Nucleon™ BACC
Genomic DNA Extraction Kit (GE Healthcare). Labeling
and hybridization were performed following the proto-
cols provided by Agilent (Agilent Oligonucleotide
Array-Based CGH for Genomic DNA Analysis protocol
v5.0). The array was analyzed with the Agilent scanner
and the Feature Extraction software (v9.1). A graphical
overview and analysis of the data were obtained using
the CGH analytics software (v3.5). For identifying dupli-
cations and deletions we used the statistical calculations
based on ADM-2 algorithm provided by the CGH analy-
tics software. According to this set-up and in the case of
autosomal genes, deletions are visualized with values of
-1 if in heterozygosity and with values of minus infinite
(-4 in CGH analytics) if in homozygosity. For three
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Page 2 of 12copies, the value would be approximately +0.6 and for
four copies the value would be +1.
The platform informations have been submitted to the
online data repository Gene Expression Omnibus (GEO)
[22], under accession number GPL9972.
Real-Time PCR
Ad hoc Real-Time PCR assays were designed for the
COL6A2 intron 1A deletion and the CNVs identified
within the ITGB1 and ITGA5/ITGA genomic regions
(Table 1 and Additional file 1). For confirming COL6A2
intron 1A deletion, a TaqMan assay was firstly used;
MGB probe and primer design was performed by Pri-
mer Express Software 2.0 (Applied Biosystems) (FW
TTGGTCACAGGTTATGCAACA, Rev GGTGAGTTT-
CACAGCTTCAAGGA; Probe 6-FAM-AACAAGT-
TAAATAGCATGAAGTG) (see Additional file 2).
Real-Time PCR was performed in triplicate in 96-well
plates using 50 ng genomic DNA and default parameters
on the Applied Biosystems Prism 7300 system. For rela-
tive quantification, the ΔΔCT Method (Applied Biosys-
tems User Bulletin #2) was utilized. CFTR exon 15 was
Figure 1 CGH-array profile and COL6A2 gene allelic configuration. A). CGH-array profile of the COL6A2 intron 1A deletion and its schematic
representation in the context of the entire COL6A2 gene. A custom track containing the maximum theoretical deleted region spanning 2094 bp
(blue bar), derived from the closest normal probes (black bars), the two deleted probes (green bars) and PCR primers pairs (red bars), was
created on UCSC Genome Browser. The two deleted probes lay at 1054 bp from exon 2. The region between the 5’-normal probe and the first-
deleted probe is covered by repetitive elements (black bar at the bottom). The two probes identifying the deletion lye within unique sequences.
B) Schematic representation of the COL6A2 gene allelic configuration in BM Patient 1, with the maternal allele (allele 1) carrying the 6-nucleotide
deletion within exon 28 and the paternal allele (allele 2) carrying the intronic deletion within intron 1A.
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were used as calibrators for each experiment. Specific
assays based on SYBR-green chemistry were also
employed in order to further verify the intron 1A dele-
tion and to confirm the CNVs identified in the ITGB1
and ITGA5/ITGA7 genomic regions, (Chr10_FW
CGTGGAGATGGGATTAGTGTG, Chr10_Rev TTTGT
TGGGAATTTACTTGGTG; Chr12_FW AATTTG
CTGTTGCTGGGTCT, Chr12_Rev TCCCATACTCTC-
CATTGTCC; Chr21_FW GCCTGTCTGCCTCTTCCA,
Chr21_Rev TGTTGCATAACCTGTGACCAA) (see
Table 1 and Additional file 2).
Transcript analysis in BM Patient 1
Total RNA was isolated from confluent fibroblasts by
using an RNeasy Kit (QIAGEN, Chatsworth, CA), and
reverse transcribed using a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem, Foster
City CA). RT-PCR was performed with a forward primer
within COL6A2 exon 25 and a reverse primer within the
5’ of exon 28, as well as with a forward primer within
exon 26 and a reverse within the 3’ of exon 28, as pre-
viously described [23]. The sequence of primers
employed is available upon request.
Immunohistochemistry, electron microscopy and Western
Blot in BM Patient 1
Unfixed frozen sections of the tibialis anterior muscle
from BM Patient 1 and control were labeled with anti-
collagen VI antibody (Chemicon MAB1944) diluted
1:100, followed by FITC-conjugated anti-mouse antibody
(DAKO); sections were double-labeled with anti-perle-
can antibody (Chemicon) diluted 1:100, and revealed
with a TRITC conjugated anti-rat antibody (SIGMA).
Muscle sections were also labeled with anti-caveolin 3
(BD-Transduction), collagen IV, laminin a2 and laminin
b1 chains (Chemicon), followed by FITC-conjugated
secondary antibody, while fibronectin (Sigma) and
alpha-dystroglycan (Upstate Biotechnologies) were fol-
lowed by TRITC-conjugated antibody (Sigma, MO). The
fibroblast cultures from Patient 1 and from a control
were obtained by mechanical means from bioptic skin
fragments and set up as previously described [24].
A mouse monoclonal anti-collagen VI antibody
(MAB1944, Chemicon) was employed, and the resulting
immunoreaction was detected with a secondary FITC-
conjugated anti-mouse antibody (DAKO). For immu-
noelectron microscopy analysis, cells were incubated
with a monoclonal anti-collagen VI antibody (Chemi-
con) diluted 1:25 with Dulbecco’s modified Eagle’sm e d -
ium and with 5 or 15-nm colloidal gold-labeled IgG
(Amersham). Rotary shadowing electron microscopy was
performed as described [25].
Samples derived from skin fibroblast cultures and
muscle biopsies were prepared for Western Blot analysis
as previously described [23]. Collagen VI was detected
by immunoblotting with antibodies recognizing either
all collagen VI chains (Fitzgerald 70XR95) or the a1(VI)
chain (Santa Cruz sc-20649) alone. Antibodies recogniz-
ing AKT (Cell Signaling) and myosin (Sigma) were used
for cell culture loading and muscle samples.
Results
Patient selection and COL6-CGH array validation
Twelve patients clinically diagnosed as possessing
UCMD (6 patients) or BM (6 patients) phenotypes nega-
tive at genomic sequence analysis, and 2 patients
(1 UCMD, 1 BM) in whom a sequence analysis positive
for COL6 mutations failed to fully explain the clinical
phenotype were selected (Table 2).
Table 1 Genes, corresponding genomic regions and protein products included in the COL6-CGH micro-array design
Genes Chromosomal Coordinates (NCBI Build 35) Proteins
HSPG2 chr1:21894043-22010053 Heparan sulfate proteoglycan 2
COL6A3 Chr2:237914662-238204820 Collagen, type VI, alpha-3 chain
COL29A1;
COL6A6
Chr3:131447049-131978580 Collagen, type XXIX, alpha 1
Collagen type VI alpha 6
ITGA1;
ITGA2
chr5:52019893-52526365 Integrin, alpha 1
Integrin, alpha 2
TNXB chr6:32116611-32186183 Tenascin XB
ITGB1 chr10:33130501-33364492 Integrin, beta 1
DCN chr12:90041504-90075827 Decorin
ITGA5;
ITGA7
chr12:52975314-54487894 Integrin, alpha 5;
Integrin, alpha 7
CSPG4 chr15:73654019-73892151 Chondroitin sulfate proteoglycan 4
COL6A1;
COL6A2
chr21:46126091-46474147 Collagen, type VI, alpha 1 chain Collagen, type VI, alpha 2 chain
BGN chrX:152181258-152395851 Biglycan
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Page 5 of 12One BM patient (Patient 1) had previously been
described by Demir et al.( #1 0 ,F a m i l y8 ) ,w h ol i n k e d
the disease in this family to chromosome 21q22.3 [26].
This patient carries a heterozygous small deletion in
exon 28 of the COL6A2 gene (NM_001849, c.
2947_2952del6, p.Asp983_Val984del) inherited from the
healthy mother. Patient 2 (UCMD) bears a heterozygous
missense alteration (NM_001848, c.350 C>T, V117A)
within COL6A1 exon 3, inherited from the unaffected
father. The V117A substitution noted in this patient had
not previously been described, so in order to evaluate
the pathogenic effect of this missense variation, poly-
morphism phenotyping predictions were obtained by
PolyPhen [27] and SIFT [28] with contrasting results:
PolyPhen predicted a benign variation whereas SIFT
foresaw a harmful effect of the V117A substitution. Sub-
sequently, amino acid conservation of V117 was ana-
lyzed, and sequence alignment between distant species
showed high conservation of the residue in the VWFA1
domain (data not shown). The screening of 200 control
chromosomes excluded it as a common polymorphism.
The COL6-CGH array was designed to cover the
regions of genes COL6A1-A2-A3-A5 and -A6 and a
group of genes functionally related to collagen VI (Table
1). Ten possible candidate genes were considered on the
basis of the following criteria: either i) their direct inter-
action with collagen VI, as in the case of HSPG2 [13],
ITGA1, ITGA2, ITGB1 [14], DNC and BGN [15]; ii)
their secondary involvement in collagen VI-deficient tis-
sues, as in NG2-proteoglycan [16,17], ITGA5 and
ITGA7 [18,19], or iii) their mutations causing an over-
lapping phenotype with collagen VI-related myopathies,
as in TNXB [20]. COL6A5 (COL29A1) and COL6A6,
which are expressed in skeletal muscle, were also
included since collagen VI alpha1-deficient mice do not
express collagen VI alpha 5 or alpha 6 chains [21].
The full coding region of all selected genes was included,
together with intronic sequences and 100 kb at the 5’ and
3’ of the first and last exons, respectively. The array was
technically validated before commencing by using DNA
from 8 normal controls; no CNVs were detected.
Two novel CNVs were identified in BM patients 4 and
5 (Table 1 and Additional File 2). The first was a 1.4 Kb
deletion, located 35 Kb downstream the ITGB1 gene
and the second was a 1.7 Kb duplication in the inter-
genic region between ITGA5 and ITGA7. Both CNVs
were confirmed by Real-Time PCR analysis (data not
shown), but the occurrence of both variations in unaf-
fected family members and healthy controls from the
general population permitted exclusion of their patho-
genic significance (see Additional File 2).
The complete CGH datasets have been submitted to
the online data repository Gene Expression Omnibus
[22], under accession number GSE20025.
T
a
b
l
e
2
:
S
u
m
m
a
r
y
o
f
c
l
i
n
i
c
a
l
a
n
d
g
e
n
o
m
i
c
d
a
t
a
i
n
t
h
e
a
n
a
l
y
z
e
d
B
M
/
U
C
M
D
p
a
t
i
e
n
t
s
(
C
o
n
t
i
n
u
e
d
)
1
0
(
U
C
M
D
)
[
1
1
]
-
S
p
o
r
a
d
i
c
F
B
i
r
t
h
w
i
t
h
d
e
l
a
y
i
n
m
o
t
o
r
m
i
l
e
s
t
o
n
e
s
8
A
b
l
e
t
o
w
a
l
k
4
U
L
a
n
d
L
L
n
o
n
e
F
i
n
g
e
r
s
F
o
l
l
i
c
u
l
a
r
h
y
p
e
r
p
l
a
s
i
a
n
o
r
m
a
l
8
5
%
n
o
r
m
a
l
R
e
d
u
c
e
d
a
t
B
M
o
f
m
u
s
c
l
e
f
i
b
e
r
s
-
1
1
(
U
C
M
D
)
-
S
p
o
r
a
d
i
c
M
2
y
r
s
,
h
y
p
e
r
l
a
x
i
t
y
a
n
d
h
y
p
e
r
C
K
8
A
b
l
e
t
o
w
a
l
k
1
h
i
p
f
l
e
x
-
3
k
n
e
e
s
e
x
t
F
i
n
g
e
r
s
,
h
i
p
,
k
n
e
e
s
,
a
n
k
l
e
s
N
o
n
e
n
o
n
e
2
3
3
%
n
o
r
m
a
l
N
D
-
1
2
(
U
C
M
D
)
-
S
p
o
r
a
d
i
c
F
1
8
m
o
,
u
n
a
b
l
e
t
o
w
a
l
k
3
1
A
b
l
e
t
o
w
a
l
k
2
4
m
o
-
1
2
y
r
s
N
e
c
k
,
t
r
u
n
k
,
e
l
b
o
w
s
,
f
i
n
g
e
r
s
,
h
i
p
s
,
k
n
e
e
s
,
a
n
k
l
e
s
N
o
n
e
n
o
n
e
1
.
5
6
2
%
n
o
r
m
a
l
N
o
r
m
a
l
a
m
o
u
n
t
a
n
d
l
o
c
a
l
i
z
a
t
i
o
n
-
1
3
(
U
C
M
D
)
-
S
p
o
r
a
d
i
c
F
B
i
r
t
h
,
f
l
o
p
p
i
n
e
s
s
3
W
a
l
k
e
d
1
8
m
o
-
p
r
e
s
e
n
t
F
i
n
g
e
r
s
,
k
n
e
e
s
,
a
n
k
l
e
s
F
i
n
g
e
r
s
F
o
l
l
i
c
u
l
a
r
h
y
p
e
r
p
l
a
s
i
a
2
N
D
N
D
R
e
d
u
c
e
d
a
t
t
h
e
B
M
o
f
m
u
s
c
l
e
f
i
b
e
r
s
-
1
4
(
U
C
M
D
)
-
S
p
o
r
a
d
i
c
M
B
i
r
t
h
4
A
b
l
e
t
o
w
a
l
k
a
t
3
y
r
s
C
o
n
g
e
n
i
t
a
l
k
y
p
h
o
s
i
s
F
i
n
g
e
r
s
F
o
l
l
i
c
u
l
a
r
h
y
p
e
r
p
l
a
s
i
a
n
o
r
m
a
l
N
D
n
o
r
m
a
l
N
D
-
*
C
r
e
a
t
i
n
e
k
i
n
a
s
e
l
e
v
e
l
:
t
i
m
e
s
t
h
e
u
p
p
e
r
v
a
l
u
e
o
f
n
o
r
m
a
l
.
U
L
:
u
p
p
e
r
l
i
m
b
s
;
L
L
:
l
o
w
e
r
l
i
m
b
s
;
A
D
:
a
u
t
o
s
o
m
a
l
d
o
m
i
n
a
n
t
;
y
r
s
:
y
e
a
r
s
;
m
o
:
m
o
n
t
h
s
;
N
D
:
n
o
t
d
o
n
e
;
S
k
M
:
s
k
e
l
e
t
a
l
m
u
s
c
l
e
;
B
M
:
b
a
s
e
m
e
n
t
m
e
m
b
r
a
n
e
Bovolenta et al. BMC Medical Genetics 2010, 11:44
http://www.biomedcentral.com/1471-2350/11/44
Page 6 of 12Identification of a pure intronic deletion in intron 1A of
the COL6A2 gene in BM patient 1
In early infancy, Patient 1 (BM) (Table 2) attained nor-
m a lm o t o rm i l e s t o n e sa n dw a l k e da t1 5m o n t h so fa g e .
However, aged 3 and a half, she began to have difficulty
running. Creatine kinase was 3.5 times the upper limit
of normal, and examination at age 21 revealed a short
stature, excessive weight and bilateral club foot. The
patient was able to walk and climb stairs without sup-
port, but was unable to run. Mild facial and limb/girdle
weakness and moderate axial and distal weakness were
noted. The patient was unable to bury the eyelashes
completely or to flex neck against gravity, and digitorum
extension weakness was evident. The patient suffered
contractures of the neck, elbows, fingers, knees and
ankles, combined with finger extension hypermobility
when the wrist was flexed. Her skin was rough and che-
loidal, and nails were dystrophic. Forced vital capacity
was 52%, and cardiac examination evidenced no
abnormality. Examination at age 30 years revealed a
relatively stable condition, with only the ability to get up
from the floor having been further compromised.
In BM Patient 1, CGH analysis revealed the presence
o fad e l e t i o nw i t h i ni n t r o n1 Ao ft h eCOL6A2 gene
(NM_001849). This deletion was detected by two over-
lapping probes which covered 95 base pairs: the
5’-deleted probe lying 12.237 nucleotides from exon 1A,
and the 3’-deleted probe located 999 nucleotides from
exon 2. The two flanking probes, which showed normal
hybridization levels, were localized respectively, 1900
nucleotides from the proximal 5’-deleted probe and 194
nucleotides from the distal 3’-deleted probe. Thus, the
identified deletion spans a maximum theoretical region
of 2094 bp, and is located 1 kb upstream of the first
COL6A2 coding exon (exon 2). Comparative sequence
analysis using the two deleted probes identified a geno-
mic region lying adjacent to a cluster of repetitive ele-
ments (Figure 1A) [29].
Real-Time PCR analysis performed using two different
assays, one based on SYBR-green and the other on Taq-
Man chemistries, confirmed the occurrence of the dele-
tion, which was inherited from the healthy father (see
Additional File 3). Analysis of 100 control subjects from
the normal population by Real-Time PCR failed to iden-
tify the COL6A2 intron deletion.
Genotypic analysis of the proband’s parents showed
the intronic deletion and the exon 28 small mutations
in trans, denoting autosomal recessive transmission.
An attempt to amplify by junction PCR the deletion
breakpoint with primers outside the maximum theoreti-
cal deleted region was unsuccessful, and sequencing
analysis of the PCR products obtained using different
sets of primers failed to identify the mutated allele. This
suggests the possibility of a complex rearrangement/
inversion of the involved genomic region (Figure 1A).
Occurrence of monoallelic COL6A2 transcription in BM
Patient 1 fibroblasts
In order to assess the pathogenic meaning of the identified
intronic deletion found in BM Patient 1, fibroblasts were
harvested and cultured prior to RNA analysis. This analy-
sis was focused on the terminal region of the COL6A2
transcript, from exon 26 (harboring two common poly-
morphisms (Ala698Ala and Gly699Gly), heterozygous at
the genomic analysis) to exon 28 (the site of the maternal
heterozygous 6-nucleotide deletion). Direct sequencing of
the amplified fragments revealed the presence of a
pseudo-homozygosity for the exon-28 deletion, as well as
Figure 2 COL6A2 genomic and transcript analysis in BM Patient 1 and his father. A) Sequence chromatograms of BM Patient 1 showing
the maternal deletion within exon 28 (GACGTG) (left) and two polymorphisms (c.2094 G>A - A698A; C.2097 C>T - G699G) within exon 26 (black
vertical arrows) (right) occurring heterozygously at the DNA level (upper panel) and pseudo-homozygously at the RNA level (lower panel). B)
Sequence chromatograms in the BM Patient 1 father showing that the exon 26 polymorphisms (c.2094 G>A - A698A; C.2097 C>T - G699G) occur
heterozygously at the DNA level (upper panel). At the RNA level (lower panel) the nucleotide variants that are undetectable in the BM Patient 1
(c.2094 G and c.2097 C), are only barely visible in the father.
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Page 7 of 12for the polymorphisms within exon 26 (Figure 2). This
implies that the allele carrying the intronic deletion is not
transcribed at appreciable levels.
In order to strengthen the case for a relationship
between the identified intronic deletion and the tran-
scriptional behavior, RNA analysis was performed on cul-
tured skin fibroblasts from the patient’sf a t h e r .T h et w o
exon 26 polymorphisms (Ala698Ala; Gly699Gly) were
found to be heterozygous at the genomic level, although
their transcription was strongly imbalanced. The
nucleotide variant of the polymorphisms (c.2094 G>A -
A698A; C.2097 C>T - G699G) that was completely unde-
tectable in the proband’s RNA (G and C, respectively),
was only barely visible in cells from the father (Figure 2).
Collagen VI expression in muscle and cell cultures from
BM Patient 1
Muscle biopsy of Patient 1 revealed a mild reduction in
collagen VI in the endomysium (Figure 3A) in comparison
with control (Figure 3E). Double labeling with anti-perle-
can antibody showed a normal pattern, attesting the integ-
rity of the basement membrane. Alpha-dystroglycan,
caveolin 3, fibronectin, and laminin a2c h a i n s( d a t a
not shown) were normally expressed, as was collagen IV
(Figure 3D), while laminin b1 chain labeling was reduced
around the muscle fibers and preserved at the basement
membrane of blood capillary vessels (Figure 3C). In cul-
tured skin fibroblasts, a mildly reduced expression of col-
lagen VI protein was associated with an altered
organization of the microfibrillar network: the immuno-
fluorescence pattern was characterized by a coarser tex-
ture than normal with fewer thinner fibrils (Figure 4A).
A finely structured collagen VI network was no longer
visible, while thicker fibers were still present. Electron
microscopy analysis of rotary-shadowed replicas of
patient’s in vivo-labeled fibroblasts showed the presence of
thick collagen VI fibrils, constituted by several parallel
microfilaments, while regularly developed webs of inter-
connected and cross-linked filaments like those seen in
control fibroblasts were absent (Figure 4C-E). Western
blot of fibroblast cultures and muscle biopsy samples
using two different antibodies recognizing either all col-
lagen VI chains or the a1(VI) chain alone revealed a quan-
titative deficiency of collagen VI in the patient, as
compared to an unaffected control (Figure 5). The reduced
amount of collagen VI in skeletal muscle was confirmed
by immunoblotting for myosin, used as a loading control
for normalizing the amount of muscle tissue.
Discussion
Molecular genotyping of UCMD and BM patients is
currently performed by extensive sequencing of
COL6A1, A2 and A3 genes. Unfortunately, however, the
PCR-based techniques used in routine screening miss
g r o s sr e a r r a n g e m e n t sa sw e l la sC N V sw h i c he x c e e dt h e
dimensional limitations of PCR amplification. Further-
more, molecular analysis fails to identify the causative
mutation in a significant percentage of patients, ranging
from 20-25% in UCMD to 35-40% in BM [5]. This rela-
tively low detection rate of current molecular approaches
in collagen VI myopathies could be ascribed to allelic het-
erogeneity (linked to the abovementioned limitations of
PCR-based techniques) and/or genetic heterogeneity. This
latter hypothesis implies that UCMD/BM phenocopies
Figure 3 Immunohistochemical analysis on muscle biopsy from
BM patient 1. Immunofluorescence analysis on muscle sections of
BM Patient 1 (A-D) and control (E-H) of collagen VI (A, E), perlecan
(B, F), laminin b1( C, G) and collagen IV (D, H). A small reduction in
collagen VI in the patient’s endomysium (A) was observed in
comparison with control (E). However, collagen VI was expressed
normally around the blood vessels (arrows, A). Double-labeling with
anti-perlecan antibody revealed a normal pattern (B) as well in the
control section (F). Laminin b1 expression was reduced at the basal
lamina of muscle fibers, while being expressed normally around the
capillary walls (arrows, C). Collagen IV labeling showed a normal
pattern around both vessels and muscle fibers (D). Bar, 40 μm.
Bovolenta et al. BMC Medical Genetics 2010, 11:44
http://www.biomedcentral.com/1471-2350/11/44
Page 8 of 12could occur, due to mutations in different, still unidenti-
fied genes.
In the last few years, novel genomic-based technolo-
gies have been reported as an efficient and improved
alternative to PCR in molecular diagnosis. Oligonucleo-
tide array-based CGH was initially developed to detect
major changes in chromosomal copy number [30], and
since then both commercial and custom arrays have
been also used to discern these changes in selected
genomic regions of interest [31,32]. The DMD gene was
a perfect candidate to test the validity of this approach,
d u et ot h el a r g es i z ea n dh i g hn u m b e ro fg r o s sc o p y
number variations apparent in this condition. Moreover,
different custom arrays have already been validated for
the exploration of both coding [33] and non-coding
regions of the gene [34-36]. For COL6 genes, the possi-
bility that genomic dosage imbalance or large CNVs
occur with significant frequency in UCMD/BM patients
still remains untested.
With the aim of increasing the sensitivity of molecular
diagnosis in collagen VI-related disorders, a custom oli-
gonucleotide-based CGH array able to detect CNVs in
coding and non-coding regions of the COL6A1, A2, A3,
and the A5 and A6 genes recently discovered to encode
novel collagen VI chains [21,37] was designed. More-
over, in order to investigate genetic heterogeneity, the
genomic regions of other genes selected on the basis of
their known or hypothetical functional relationship with
Figure 4 Immunohistochemical analysis and electron microscopy on fibroblasts. Reduced amount of collagen VI microfilamentous network
was detected in the extracellular matrix secreted by fibroblasts of BM Patient 1 (A) as compared to control fibroblasts (B). The microfibrillar
network in the patient’s fibroblasts showed an altered organization, characterized by a coarser texture than normal (A, Arrows) Fibroblast density
was monitored by DAPI staining of the nuclei. Bar, 20 μm. Electron microscope examination of rotary-shadowed cultured fibroblasts from control
(C) and BM Patient 1 (D-E), labeled with anti-collagen VI and revealed with a secondary antibody conjugated with 5-nm colloidal gold particles.
Ultra-structural analysis of the rotary-shadowed fibroblasts revealed the presence of collagen VI fibrils constituted by several parallel running
microfilaments in BM Patient 1 (D, E), while regular webs of interconnected microfilaments, like those shown in control fibroblasts (C), were
absent. Bar, 200 nm.
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Page 9 of 12collagen VI were also included in the design, as all these
genes potentially represent candidates for mutations
that could underlie phenocopies of collagen VI-related
diseases [38,39,13,15,40-42].
By testing our array in 14 selected UCMD/BM patients,
we identified a deep intronic deletion in the COL6A2
gene in a BM patient occurring in compound heterozyg-
osity with a small exonic mutation previously detected by
sequencing. Despite not definitively proven, due to the
failure to amplify the deletion breakpoint, nevertheless
the pathogenic potential of this intronic mutation is sup-
ported by the transcriptional impairment of the mutated
allele that was demonstrated both in the proband and in
her healthy carrier father. The COL6A2 gene is charac-
terized by a first-coding exon (exon 2) separated from
two alternatively spliced 5’-untranslated exons (exon 1
and 1a) by a huge 12 kb intron (intron 1A) [43].
Deletion of this intron may abolish cis-acting elements
and/or the binding of trans-acting factors involved in
the regulation of COL6A2 gene expression. Alternatively,
the deletion itself might be the marker for a complex
genomic rearrangement occurring in the COL6A2 gene
that inverts or scrambles the entire genomic configura-
tion. The failure of PCR to amplify the deletion junction
seems to support this hypothesis.
This study documents an additional case of a BM
patient with a compound heterozygous genotype for
recessive COL6A2 mutations. Interestingly, both of the
autosomal recessive BM casesw ep r e v i o u s l yd e s c r i b e d
carried a peculiar allele combination consisting of a trun-
cating mutation partnered by missense changes within
the a2(VI) C2 region [3]. Despite different (null muta-
tion/in-frame deletion), the allelic configuration of BM
Patient 1 also indicates the presence of a mutated a2(VI)
C2 domain, derived from a single allele, similar to the
recessive BM cases previously described [3]. The findings
in this patient also substantiate the observation that
recessive BM mutations, unlike the classical dominant
cases, affect collagen VI expression in skeletal muscle [3],
as attested by immunohistochemical and biochemical
analyses showing a decreased amount of this protein.
I nt h et w e l v ep a t i e n t sw h ot e s t e dn e g a t i v eu p o ng e n o -
mic sequence analysis, no CNVs were identified in COL6
genes using the CGH array. Even though the limited size
of the analyzed patient cohort hampered definitive esti-
mations, our results did exclude a relevant incidence of
CNVs within COL6 genes, thereby supporting UCMD/
BM genetic heterogeneity. Likewise, no pathogenic CNVs
were identified among the other genomic regions poten-
tially harboring candidate BM/UCMD genes that were
explored in the array. Nevertheless, these results do not
rule out the possibility that genetic heterogeneity could
account for some COL6A1-3-negative patients and sug-
gest that high-throughput sequencing technologies could
Figure 5 Western Blot analysis of fibroblasts. Western blot analysis of collagen VI in cultured skin fibroblasts and in muscle biopsies from
control (CTRL) and BM Patient 1 (BM1) was performed. Samples corresponding to the cell layer (left panel, 20 μg) and medium (middle panel,
30 μg) in the presence or absence of L-ascorbate, and muscle extracts (right panel, 15 μg), were separated by electrophoresis under reducing
conditions in 3-8% polyacrylamide-gradient gel. Collagen VI was detected by immunoblotting with antibodies recognizing either all collagen VI
chains (Fitzgerald 70XR95) or the a1(VI) chain (Santa Cruz sc-20649). Migration of the collagen VI chains is indicated on the right and molecular
weight markers (kDa) are shown on the left. Control for loading was performed by antibodies against AKT (cell layers) or myosin (muscle
biopsies).
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Page 10 of 12represent more appropriate future approaches for detec-
tion of point mutations. In fact, these innovative tools
could allow significant enlargement of the spectrum of
functionally related collagen VI genes to be explored
sequentially via CNV identification and re-sequencing for
detection of point mutations.
Conclusions
The described COL6-CGH array could represent a use-
ful complementary diagnostic test, useful for increasing
the sensitivity of molecular analysis in patients with a
clinical diagnosis of collagen VI-related disorders. The
limited size of the patient cohort we analyzed hampered
estimation of copy number variation frequency, but ana-
lysis of larger populations could well permit conclusions
to be drawn. In fact, this novel tool allowed us for the
first time to identify a COL6A2 mutation affecting gene
transcription deeply located within an intronic region,
and thus undetectable with all other techniques cur-
rently available. Furthermore, in recent years specific
genetic diagnosis has become mandatory for a patient to
be eligible for upcoming therapeutic trials [44], and thus
the lack of molecular diagnosis in a large percentage of
patients with collagen-VI related phenotypes makes the
search and the validation of novel diagnostic tools an
ever-more pressing issue.
Additional file 1: Gene Symbols, chromosomal coordinates, transcript
and protein identifiers for the genes included in the COL6-CGH micro-
array design.
Additional file 2: CNVs identified in BM Patients 4 and 5. A) COL6-
CGH array result in BM Patient 4, showing the deletion of about 1.4 kb
identified on chromosome 10, 35 Kb downstream of the ITGB1 gene. B)
The CNV on chromosome 10 was validated by Real-Time PCR, and its
segregation was analyzed in Patient 4’s family; the deletion was present
in three unaffected subjects (2-ΔΔCT values of 0.44, 0.41, 0.45) and absent
in the symptomatic proband’s mother and cousin (2-ΔΔCT values of 0.99
and 0.86), thus not linked to the disease. C) COL6-CGH array result in BM
Patient 5, showing the 1.7 Kb duplication occurring in the intergenic
region between ITGA5 and ITGA7 on chromosome 12.
Additional file 3: Real Time PCR experiments confirming COL6A2
intron 1A deletion in BM Patient 1 and in the father. In the upper
panel, the results obtained with an intron 1A specific TaqMan assay are
shown. Red plots correspond to utilized reference gene (CFTR exon 15)
whereas green plots refer to target sequence within intron 1A. The Ct
(threshold cycle) values of the target sequence are in line with the
reference in control sample (unaffected subject) and in proband’s
mother, whereas the target Ct values are higher than reference in BM
Patient 1 and in the father, attesting the deletion (2-ΔΔCT values were
0.47 and 0.53 in BM Patient 1 and in the father respectively, whereas the
2-ΔΔCT value was 0.97 in the proband’s mother). In the lower panel the
position of the primers utilized in the SYBR green assay (blu) and of
primers and probe utilized in the TaqMan assay (pink), are shown in
respect to the deleted region (in bold).
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